Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGMS2 | Q8NHU3 | 8/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL360801 | 0.85 | SGMS2 (0.41) | SGMS2ALDH1A1LMNACYP1A2CYP2C9 | |
| SCHEMBL412642 | 0.78 | NPSR1 (0.47) | ALDH1A1CYP1A2CYP2C9CYP2C19NPSR1 | |
| SCHEMBL10624782 | 0.74 | MAPT (0.46) | ALDH1A1CYP1A2CYP2C9CYP2C19NPSR1 | |
| SCHEMBL15569253 | 0.73 | SGMS2 (0.40) | SGMS2ALDH1A1LMNACYP1A2CYP2C9 | |
| SCHEMBL410966 | 0.71 | HSD17B10 (0.44) | ALDH1A1CYP1A2NPSR1MAPTGAA | |
| SCHEMBL29031402 | 0.70 | ALDH1A1 (0.51) | ALDH1A1LMNANPSR1MAPTGAA | |
| SCHEMBL28000890 | 0.68 | NPSR1 (0.57) | ALDH1A1LMNACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL11796802 | 0.68 | CTSL (0.40) | ALDH1A1CYP1A2CYP2C9CYP2C19NPSR1 | |
| SCHEMBL31174454 | 0.67 | TDP1 (0.56) | ALDH1A1LMNACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL632551 | 0.67 | TDP1 (0.56) | ALDH1A1LMNACYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518990-B2 | Cancer treatment | ONCOPHOR, LLC (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518990-B2 | Cancer treatment | ONCOPHOR, LLC (US) | 2013-08-27 | — | — | US | disclosed |
| US-8329756-B2 | Drug for treatment of colon cancer | ONCOPHOR, LLC (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329756-B2 | Drug for treatment of colon cancer | ONCOPHOR, LLC (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329756-B2 | Drug for treatment of colon cancer | ONCOPHOR, LLC (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120065208-A1 | CANCER TREATMENT | Electronic Patent Assignments System (EPAS) | 2012-03-15 | — | — | US | disclosed |
| US-20120065208-A1 | CANCER TREATMENT | Electronic Patent Assignments System (EPAS) | 2012-03-15 | — | — | US | disclosed |
| US-20110257270-A1 | DRUG FOR TREATMENT OF COLON CANCER | ONCOPHOR, LLC | 2011-10-20 | — | — | US | disclosed |
| US-20110257270-A1 | DRUG FOR TREATMENT OF COLON CANCER | ONCOPHOR, LLC | 2011-10-20 | — | — | US | disclosed |
| US-20110257270-A1 | DRUG FOR TREATMENT OF COLON CANCER | ONCOPHOR, LLC | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257270-A1 | DRUG FOR TREATMENT OF COLON CANCER | SLC10A2, APC, KRAS | SGMS2 1098/4885ALDH1A1 121/4885LMNA 3445/4885 |
| US-20120065208-A1 | CANCER TREATMENT | BRCA1, VHL, MGMT | SGMS2 717/4885ALDH1A1 618/4885LMNA 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.